Mechanisms of interleukin‐10‐mediated immune suppression
- 1 June 2001
- journal article
- review article
- Published by Wiley in Immunology
- Vol. 103 (2), 131-136
- https://doi.org/10.1046/j.1365-2567.2001.01235.x
Abstract
Specific immune suppression and induction of anergy are essential processes in the regulation and circumvention of immune defence. Interleukin-10 (IL-10), a suppressor cytokine of T-cell proliferative and cytokine responses, plays a key regulatory role in tolerizing exogenous antigens during specific immunotherapy (SIT) of allergy and natural exposure to antigens. Specific T-cell tolerance is directed against the T-cell epitopes of an antigen and characterized by suppressed proliferative and T helper type 1 (Th1) and type 2 (Th2) cytokine responses. IL-10 elicits tolerance in T cells by selective inhibition of the CD28 co-stimulatory pathway and thereby controls suppression and development of antigen-specific immunity. IL-10 only inhibits T cells stimulated by low numbers of triggered T-cell receptors and which therefore depend on CD28 co-stimulation. T cells receiving a strong signal from the T-cell receptor alone, and thus not requiring CD28 co-stimulation, are not affected by IL-10. IL-10 inhibits CD28 tyrosine phosphorylation, the initial step of the CD28 signalling pathway, and consequently the phosphatidylinositol 3-kinase p85 binding to CD28. Together these results demonstrate that IL-10-induced selective inhibition of the CD28 co-stimulatory pathway acts as a decisive mechanism in determining whether a T cell will contribute to an immune response or become anergic.Keywords
This publication has 72 references indexed in Scilit:
- Mechanisms of allergen‐specific immunotherapyAllergy, 2000
- Effects of peptide therapy on ex vivo T-cell responsesJournal of Allergy and Clinical Immunology, 1998
- Nasal Immunotherapy in Weed-Induced Allergic RhinitisAnnals of Allergy, Asthma & Immunology, 1997
- IL-10: a potential therapy for allergic inflammation?Immunology Today, 1997
- DiscussionImmunology Today, 1997
- The expanding universe of T-cell subsets: Th1, Th2 and moreImmunology Today, 1996
- Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1.The Journal of Experimental Medicine, 1993
- CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clonesNature, 1992
- Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.The Journal of Experimental Medicine, 1991
- Immunoregulatory T-Cell PathwaysAnnual Review of Immunology, 1983